Community hub
0 subscribers7 pages, 0 posts
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Welcome to the community hub built to collect knowledge and have discussions related to CYB005.
Nothing was collected or created yet.
CYB005
View on Wikipediafrom Wikipedia
| Clinical data | |
|---|---|
| Other names | CYB-005; Deuterated phenethylamine; Deuterated phenethylamine derivative |
| Drug class | Serotonin receptor agonist; Serotonergic psychedelic; Antiinflammatory drug[1] |
CYB005, or CYB-005, also known as deuterated phenethylamine derivative, is a serotonin receptor agonist and serotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment of psychiatric disorders and neuroinflammation.[2][3][1]
Interactions
[edit]Pharmacology
[edit]Pharmacodynamics
[edit]CYB005 acts as a serotonin receptor agonist and is a serotonergic psychedelic.[2][1] In addition, CYB005 may also inhibit serotonin and dopamine reuptake.[1]
Chemistry
[edit]It is a phenethylamine derivative and a deuterated compound.[2][3][1] The exact chemical structure of CYB005 does not yet seem to have been disclosed.[2][1] However, it appears to be closely related to CYB210010, which itself is non-deuterated.[4][5][6] In addition, CYB005's developer has patent protection for the compound, indicating that its chemical structure has been published in the patent literature.[2][4][7]
Development
[edit]As of October 2024, CYB005 is in the research or preclinical stage of development.[2][3] It has been in this developmental stage since at least 2022.[1] The drug is under development by Cybin.[2][3][1] Other related drugs include the deuterated tryptamines CYB003 and CYB004.[1][8]
See also
[edit]References
[edit]- ^ a b c d e f g h i Cano GH, Dean J, Abreu SP, Rodríguez AH, Abbasi C, Hinson M, Lucke-Wold B (December 2022). "Key Characteristics and Development of Psychoceuticals: A Review". Int J Mol Sci. 23 (24) 15777. doi:10.3390/ijms232415777. PMC 9779201. PMID 36555419.
Table 1. Biochemical structures, mechanisms, and receptor functions of twenty psychoceutical drugs.: [...] Drug Name: Phenethylamine derivative (CYB005): Chemical Structure: *. Target type: –. Method of Action: CYB005 inhibits serotonin and dopamine transporters within the synaptic cleft. [...] These drugs generally bind to CNS G-protein receptors within the 5-HT family, such as 5-HT1A, 5-HT2A, and 5-HT2B, and act agonistically [9,13–15,17,18]. Additionally, two of these, ecstasy and CYB005 (phenethylamine derivative [20]), block the reuptake of serotonin, increasing the serotonin levels within the synaptic cleft [12,21,22]. [...] According to preclinical data, CYB005, a phenethylamine derivative, aims to inhibit serotonin transporters within the synaptic cleft [20–22]. [...] Studies on [...] CYB005 [...] were not found in the literature search, so this information was obtained through the websites of their respective pharmaceutical companies. [...] Table 2. Highlights of the psychoceutical benefits.: Drug: CYB005 (Phenethylamine derivative). Benefit: Treats neuroinflammation and psychiatric conditions. [...] Three [deuterated] drugs that researchers have been working on are [...] CYB005 (for neuroinflammation). [...] Finally, CYB005 is a phenethylamine derivative currently in preclinical development [55], which has the potential to treat neuroinflammation and psychiatric conditions [20]. [...] Of the 20 drugs, [...] CYB005 [...] do not currently have completed clinical trials.
- ^ a b c d e f g "CYB 005". AdisInsight. 28 October 2024. Retrieved 10 November 2024.
CYB 005 is a phenethylamine derivative is being developed by Cybin for the treatment of treatment resistant psychiatric disorders.
- ^ a b c d "Delving into the Latest Updates on CYB-005 with Synapse". Synapse. 1 November 2024. Retrieved 10 November 2024.
- ^ a b "Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program". Yahoo Finance. 24 October 2024. Retrieved 10 November 2024.
- ^ Varty GB, Canal CE, Mueller TA, Hartsel JA, Tyagi R, Avery K, Morgan ME, Reichelt AC, Pathare P, Stang E, Palfreyman MG, Nivorozhkin A (April 2024). "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist". J Med Chem. 67 (8): 6144–6188. doi:10.1021/acs.jmedchem.3c01961. PMID 38593423.
- ^ Palfreyman M, Varty G, Canal C, Hartsel J, Tyagi R, Avery K, Morgan M, Mueller T, Reichelt A, Pathare P, Stang E, Nivorozhkin A (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P405. Discovery and Preclinical Characterization of the Phenylalkylamine, CYB210010, a Potent and Long-Acting Serotonin 5-HT2A Receptor Agonist". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (299–299). doi:10.1038/s41386-023-01756-4. PMC 10729596. PMID 38040810.
- ^ "Therapeutic phenethylamine compositions and methods of use". Google Patents. 18 August 2021. Retrieved 10 November 2024.
- ^ Peplow M (June 2024). "Next-generation psychedelics: should new agents skip the trip?". Nat Biotechnol. 42 (6): 827–830. doi:10.1038/s41587-024-02285-1. PMID 38831049.